Wegovy vs Liraglutide: Head-to-Head Efficacy Comparison

How the Two Drugs Compare by Mechanism

Both Wegovy and liraglutide belong to the GLP-1 receptor agonist class. They mimic the incretin hormone glucagon-like peptide-1, slowing gastric emptying, reducing appetite, and enhancing insulin secretion in a glucose-dependent manner.

The difference sits in molecular engineering. Semaglutide (Wegovy's active ingredient) was designed with a C-18 fatty diacid chain and a small amino acid modification at position 8 that resists degradation by dipeptidyl peptidase-4 (DPP-4). This structural change extends its plasma half-life to approximately 165 hours, roughly seven days, enabling once-weekly dosing [1]. Liraglutide, the older molecule, carries a C-16 fatty acid chain and has a half-life of about 13 hours, requiring daily injection [2].

Both drugs bind the same GLP-1 receptor, yet semaglutide demonstrates higher binding affinity. A 2017 pharmacology analysis published in the Journal of Medicinal Chemistry reported that semaglutide's receptor binding potency exceeded liraglutide's by roughly threefold [3]. That pharmacologic edge partly explains the clinical gap in weight-loss outcomes.

STEP-1 vs SCALE: The Key Trial Data

Semaglutide 2.4 mg outperformed liraglutide 3.0 mg by a wide margin across their respective registration trials, though these were separate placebo-controlled studies, not a single head-to-head comparison.

In STEP-1 (N=1,961), participants receiving semaglutide 2.4 mg once weekly lost a mean of 14.9% of body weight at 68 weeks, compared with 2.4% in the placebo arm [1]. More than one-third of participants (34.8%) achieved at least 20% weight loss. The trial enrolled adults with a BMI of 30 or greater (or 27 or greater with at least one weight-related comorbidity) and excluded patients with diabetes.

The SCALE Obesity and Prediabetes trial (N=3,731) randomized patients to liraglutide 3.0 mg daily or placebo [2]. At 56 weeks, mean weight loss reached 8.0% with liraglutide versus 2.6% with placebo. Only 14.4% of liraglutide-treated patients hit the 10% or greater weight-loss threshold.

A cross-trial comparison must be interpreted carefully. Different baseline BMIs, run-in designs, lifestyle counseling intensity, and trial durations limit direct comparison. Still, the absolute difference (14.9% vs 8.0%) is large enough that most obesity-medicine specialists consider semaglutide the more effective agent.

"Cross-trial comparisons are inherently limited, but the magnitude of difference between semaglutide 2.4 mg and liraglutide 3.0 mg is consistent enough across endpoints to be clinically meaningful," noted the Endocrine Society's 2022 clinical practice guideline on pharmacologic management of obesity [4].

The Direct Head-to-Head: STEP-8 Trial Results

A single randomized trial did compare the two drugs directly. That trial matters more than any cross-study extrapolation.

STEP-8 (N=338) randomized adults with overweight or obesity (without diabetes) to semaglutide 2.4 mg once weekly, liraglutide 3.0 mg once daily, or matched placebos for 68 weeks [5]. The results were unambiguous. Semaglutide 2.4 mg produced 15.8% mean body-weight loss versus 6.4% with liraglutide 3.0 mg. The estimated treatment difference was -9.4 percentage points (95% CI, -12.0 to -6.8; P<0.001).

Patients on semaglutide were also more likely to reach clinically significant thresholds: 70.9% lost at least 10% of body weight, compared with 25.6% on liraglutide. For the 20% or greater benchmark, 55.0% of semaglutide patients qualified versus just 7.0% on liraglutide.

STEP-8 eliminated the uncertainty of cross-trial comparisons and confirmed that semaglutide 2.4 mg roughly doubles the weight loss of liraglutide 3.0 mg when tested head-to-head under identical conditions.

Dosing, Titration, and Practical Convenience

Wegovy is injected subcutaneously once per week using a prefilled pen. The titration schedule spans 16 weeks: 0.25 mg weekly for four weeks, then stepwise increases to 0.5 mg, 1.0 mg, and 1.7 mg before reaching the maintenance dose of 2.4 mg at week 17 [1].

Liraglutide requires a daily subcutaneous injection. Titration follows a similar step-up pattern over five weeks, starting at 0.6 mg daily and increasing by 0.6 mg weekly until the 3.0 mg target dose is reached [2]. That means 30 injections per month with liraglutide versus four with Wegovy.

For adherence, weekly dosing has a measurable advantage. A 2020 retrospective cohort study published in Diabetes, Obesity and Metabolism found that patients on once-weekly GLP-1 receptor agonists had 1.4 times higher odds of 12-month medication persistence compared to those on daily formulations [6]. Missing a single daily injection is more likely than missing a weekly one, and the pharmacokinetic buffer of semaglutide's long half-life makes a delayed dose less consequential.

Patients who travel frequently, have needle anxiety, or manage complex medication regimens tend to prefer the weekly option. A daily injection at the same time each day is a smaller ask than many oral medication regimens, but it still represents a meaningful difference when stacked against once-weekly administration.

Safety and Side Effect Profiles

GI side effects dominate both drugs. Nausea, vomiting, diarrhea, and constipation are the most frequently reported adverse events across all GLP-1 receptor agonist trials.

In STEP-1, 44.2% of semaglutide-treated patients reported nausea (vs. 17.4% placebo), while 24.8% experienced diarrhea [1]. In SCALE, nausea occurred in 40.2% of liraglutide patients, with diarrhea in 21.2% [2]. The rates are similar in absolute terms.

STEP-8 offered the only controlled comparison of tolerability under matched conditions. Nausea rates were comparable between the two active arms (43.9% semaglutide vs. 38.2% liraglutide), though a higher proportion of liraglutide patients (12.6%) discontinued due to GI events compared with semaglutide patients (3.2%) [5]. That finding may reflect the burden of daily dosing during symptomatic episodes rather than worse absolute tolerability.

Both drugs carry the same class-level FDA boxed warning regarding medullary thyroid carcinoma (MTC) risk observed in rodent studies. Neither agent should be used in patients with a personal or family history of MTC or multiple endocrine neoplasia syndrome type 2 [7]. Pancreatitis, gallbladder disease, and acute kidney injury are listed as warnings for both.

Serious adverse events remained low in both key trials. STEP-1 recorded serious adverse events in 9.8% of the semaglutide group versus 6.4% with placebo [1]. SCALE reported 6.2% for liraglutide versus 5.0% for placebo [2].

Cardiometabolic Benefits Beyond Weight Loss

Weight loss itself improves cardiovascular risk markers, but GLP-1 receptor agonists carry independent cardiometabolic benefits that differ in strength between the two molecules.

The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced the composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke by 20% (hazard ratio 0.80; 95% CI, 0.72 to 0.90; P<0.001) in adults with overweight or obesity and established cardiovascular disease but without diabetes [8]. This led to an expanded FDA indication for Wegovy to reduce cardiovascular risk in March 2024 [9].

Liraglutide's cardiovascular data comes from the LEADER trial (N=9,340), which tested liraglutide 1.8 mg (the diabetes dose, not the obesity dose of 3.0 mg) and found a 13% reduction in major adverse cardiovascular events [10]. No dedicated cardiovascular outcomes trial exists for liraglutide at the 3.0 mg obesity dose.

Both molecules improve hemoglobin A1c, fasting glucose, blood pressure, and lipid profiles. STEP-1 showed a 4.7 mmHg reduction in systolic blood pressure with semaglutide versus 0.5 mmHg with placebo [1]. SCALE reported a 4.2 mmHg reduction with liraglutide [2]. The glycemic and blood pressure improvements track proportionally with weight loss.

Weight Regain After Stopping Treatment

A critical consideration for both agents: weight returns after discontinuation.

The STEP-1 trial extension study showed that participants who stopped semaglutide after 68 weeks regained approximately two-thirds of the weight they had lost within one year of cessation [11]. A similar trajectory has been documented with liraglutide discontinuation in the SCALE extension data, where weight regain began within weeks of stopping treatment [2].

This pharmacologic reality applies equally to both drugs and underscores that GLP-1 therapy for obesity is a long-term, often indefinite commitment. The American Association of Clinical Endocrinology (AACE) 2023 obesity guidelines state: "Anti-obesity medications should be continued long-term when effective and tolerated, as obesity is a chronic disease requiring ongoing treatment" [12].

Neither drug is a short course. Patients and prescribers should plan for sustained therapy when initiating either medication.

Cost, Insurance Coverage, and Access

Retail pricing for both medications falls in a similar range. Wegovy lists at approximately $1,349 per month. Liraglutide 3.0 mg (branded as Saxenda) lists at roughly $1,100 to $1,350 monthly [7].

Insurance coverage varies widely. Many commercial plans cover Wegovy under specialty pharmacy benefits, though prior authorization requirements are common. Liraglutide 3.0 mg faces similar formulary restrictions. Medicare Part D historically excluded anti-obesity medications, but the Treat and Reduce Obesity Act and subsequent CMS guidance have begun expanding coverage for certain GLP-1 agents tied to cardiovascular indications.

Generic liraglutide is not yet available in the United States as of May 2026, though several biosimilar applications are in regulatory review. Wegovy's patent protections extend further, with key composition-of-matter patents not expiring until the late 2020s. When generic liraglutide does reach market, it could shift the cost calculus for patients who respond adequately to the older molecule despite its lower efficacy ceiling.

Manufacturer savings programs exist for both drugs. Novo Nordisk offers copay assistance cards for eligible commercially insured patients, reducing out-of-pocket costs to as low as $0 to $25 per month for qualifying individuals.

Who Might Still Choose Liraglutide?

Semaglutide 2.4 mg is the stronger weight-loss agent by every clinical measure. But clinical decisions are not made on efficacy alone.

Patients who cannot tolerate semaglutide's side-effect profile at higher doses may find liraglutide's daily titration offers more granular dose control. If nausea hits at 1.8 mg of liraglutide daily, a patient can hold at that dose before advancing, with finer increments than semaglutide's prefilled pen steps allow.

Some patients who have tried and discontinued semaglutide due to persistent GI symptoms have tolerated liraglutide without issue. GLP-1 receptor agonist response is individual, and switching between molecules within the class is a recognized clinical strategy per AACE guidelines [12].

Supply constraints have also played a role. During the 2023 to 2025 semaglutide shortage, liraglutide served as the primary alternative for patients who could not access Wegovy. For patients already stable on liraglutide with acceptable weight loss and metabolic improvement, switching to semaglutide is a discussion, not a mandate.

Switching Between Wegovy and Liraglutide

Transitioning from one GLP-1 receptor agonist to another requires a structured protocol, not a same-day swap.

The general clinical approach involves stopping the current agent and beginning the new one at its starting titration dose. A patient moving from liraglutide 3.0 mg to Wegovy would start at semaglutide 0.25 mg weekly and follow the full 16-week dose-escalation schedule. Skipping titration increases the risk of severe nausea, vomiting, and treatment discontinuation.

The timing depends on the direction of the switch. When moving from daily liraglutide to weekly semaglutide, the first semaglutide injection is typically given the day after the last liraglutide dose. When moving from weekly semaglutide to daily liraglutide, liraglutide can start one week after the last semaglutide injection, once semaglutide concentrations have declined meaningfully.

No published consensus guideline specifies an exact washout period. Clinicians typically use pharmacokinetic reasoning: liraglutide clears within 2 to 3 days given its 13-hour half-life, while semaglutide requires 5 to 7 weeks to fully clear given its 7-day half-life. Overlapping the two agents intentionally is not recommended due to additive GI side effects.